Here is Why Apogee Therapeutics (APGE) Appears Attractive

Apogee Therapeutics (NASDAQ:APGE) is 1 of the 17 biotechnology stocks with much than 50% upside.

On January 25, Citi expert Geoff Meacham maintained a Buy standing connected Apogee Therapeutics (NASDAQ:APGE), with a $95 terms target. His forecast indicates imaginable upside of much than 37%.

Copyright: katrintimoff / 123RF Stock Photo

Selloff successful Apogee Therapeutics (APGE) stock, pursuing the merchandise of Sanofi’s Phase 3 amlitelimab data, is viewed arsenic a marketplace overreaction by Meacham. He maintains that information readout does not negatively impact prospects for the company’s APG279. This campaigner is simply a fixed-dose operation that targets some IL-13 and OX40L.

Back connected January 22, Brian Abrahams from RBC Capital lowered his standing connected Apogee Therapeutics (NASDAQ:APGE) from Outperform to Sector Perform. The expert raised the terms people from $70 to $83, implying astir 20% upside.

Abrahams noted that the conception successful which Apogee Therapeutics (NASDAQ:APGE) operates is “becoming progressively crowded with well-entrenched existing players” contempt the company’s superior drug, zumilokibart, showing imaginable arsenic a long-acting IL-13 for atopic dermatitis. He reflected connected the 108% surge successful the stock terms implicit the past year, which limits the imaginable for further gains.

Apogee Therapeutics (NASDAQ:APGE) is simply a clinical-stage biotechnology institution processing caller biologics to dainty inflammatory and immune diseases. These see atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis, and others. Its existing pipeline includes APG777, APG279, APG990, APG333, and APG808, each successful antithetic objective proceedings stages.

While we admit the imaginable of APGE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.